alexa Human Epidermal Growth Factor Receptor|OMICS International|Clinical Trials

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Human Epidermal Growth Factor Receptor

The Human Epidermal Growth Factor Receptor 2 (HER2) oncogene is responsible for encoding a transmembrane tyrosine kinase which is over expressed in 20-25% of breast cancers and is associated with a worse prognosis. The use of trastuzumab, a humanized monoclonal antibody to the HER2 extracellular domain, has been shown to improve survival in both early and metastatic HER2-positive patients, and is now the standard of care in this patient population. Despite these advances, approximately 15% of patients treated with adjuvant trastuzumab will relapse, and progressive disease often occurs after first-line trastuzumab therapy in the metastatic setting within 12 months.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on July, 2014

Top